European CHMP recommends approval of two new long-acting antiretroviral injections for the treatment of HIV-1 infection

The CHMP has recommended the approval of rilpivirine and cabotegravir, to be used together for the maintenance treatment of adults with viral load <50 copies/mL with their current antiretroviral treatment, and when the virus has not developed resistance to NNRTIs or INIs.

Source:

European Medicines Agency